Published by Josh White on 18th March 2024
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.
URL: http://www.digitallook.com/dl/news/story/34162415/...